Indivior (INDV) Share Price, News & Analysis

Company Overview

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Key Stats

• Today's Range: 714 to 745.50
• 50-Day Range: 617 to 979.50
• 52-Week Range: 548.71 to 1,751
• Volume: 401,184 shs
• Average Volume: 1.24 million shs
• Market Capitalization: £1.15 billion
• P/E Ratio: N/A
• Dividend Yield: 2.05%
• Price Target: GBX 1,650
• Consensus Rating: Buy

Indivior Stock Analysis - MarketRank™

Indivior scored higher than 48% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Indivior has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Indivior has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Indivior is -607.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Indivior is -607.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Growth Ratio

Due to a projected decrease in earnings for Indivior, their PEG ratio cannot be calculated.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for INDV.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Leadership

Indivior is a leading dividend payer. It pays a dividend yield of 4.48%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

Indivior does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for INDV.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.79

News Sentiment

Indivior has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Indivior this week, compared to 1 article on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Indivior insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.44% of the stock of Indivior is held by insiders.

Percentage Held by Institutions

85.98% of the stock of Indivior is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

INDV Stock Analysis - Frequently Asked Questions

How have INDV shares performed this year?

Indivior's stock was trading at GBX 1,024 at the beginning of the year. Since then, INDV shares have decreased by 28.4% and is now trading at GBX 733.
View the best growth stocks for 2025 here.

How do I buy shares of Indivior?

Shares of INDV stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Indivior own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Indivior investors own include Futura Medical (FUM), Bigblu Broadband (BBB), Directa Plus (DCTA), Lakehouse (LAKE), Kingfisher (KGF), Sirius XM (SIRI) and Aquila Services Group (AQSG).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: LON:INDV
• CIK: N/A
• Web: indivior.com
• Phone: +44-1753-217800
• Fax: N/A
• Employees: 1,000
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: GBX 1,650
• High Stock Price Target: GBX 1,800
• Low Stock Price Target: GBX 1,500
• Potential Upside/Downside: +124.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): GBX (1.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 692.92
• P/E Growth: -5.57
• Net Income: £-2,364,965.64
• Net Margins: -0.17%
• Pretax Margin: N/A
• Return on Equity: -0.77%
• Return on Assets: 2.37%

Debt

• Debt-to-Equity Ratio: -170.06
• Current Ratio: 0.83
• Quick Ratio: 1.52

Sales & Book Value

• Annual Sales: £1.40 billion
• Price / Sales: 0.82
• Cash Flow: GBX 274.06 per share
• Price / Cash Flow: 2.68
• Book Value: GBX (126.42) per share
• Price / Book: -5.81

Miscellaneous

• Outstanding Shares: 156,209,528
• Free Float: N/A
• Market Cap: £1.15 billion
• Optionable: Not Optionable
• Beta: 0.19